FDA Opens Door To Enhanced Applications For Quicker CMC Reviews
Executive Summary
US FDA hopes to expedite NDA and ANDA reviews and lay groundwork for eventual ICH adoption by asking sponsors to make better use of CTD's Quality Overall Summary, which could allow agency reviewers to focus on patient impact and other key factors.